Skip to main content
Join our webinar series discussing the latest developments in drug discovery. Register now.
Enquire

Domainex opens a dedicated new facility at Unity Campus to expand research operations

Domainex in the new lab at Unity Campus

Cambridge, United Kingdom, 10th February 2022 / Domainex Ltd., a leading integrated medicines research services partner, today announces it has opened a facility of over 7,000 sq ft at Unity Campus in Sawston – Cambridge’s newest science and technology park encompassing Iconix Park and The Works, and owned by leading regional property and investment firm Howard Group. 

The Domainex facility has fully equipped and operational laboratories and consolidates the Company’s footprint in the Cambridge bioscience cluster. Following two years of very strong growth for the business, Domainex is also seeking to recruit new staff members across all disciplines, with an anticipated increase in headcount of up to fifty per cent by the end of 2022.  

Commenting on the expansion, Dr Tom Mander, CEO of Domainex, stated: “On the back of the strong uptake of our services by life science organisations globally over the last two years, the investment into our new facility has allowed us to create a fully dedicated suite of labs to conduct our biology services. We have enjoyed robust growth in this area, especially in our structure-based offerings. This has the added benefit of freeing up space at our closely located Chesterford Research Park site to further expand our chemistry group.

“We are committed to attracting and retaining highly talented people and have embarked on a major recruitment drive to underpin our growth. Coupled with this, we are making significant additional investments in our people’s skills, access to other cutting-edge technologies and in R&D to bring new services to the market. These are fascinating times for Domainex, and at the outset of our 21st year of operations, we have created a strong financial position to continue our organic growth strategy. We enjoy the strong backing of our Board and shareholders to build a pre-eminent drug discovery partner.”

Domainex will be joining an existing community of biomedical companies at Unity Campus, including IONTAS, PhoreMost, Sareum and Liminal BioSciences. With only one suite remaining of circa 9000 sq ft at The Works, Howard Group is forging ahead with its plans to deliver an additional 95,000 sq ft of labs and offices across three new buildings. With a detailed planning application currently under review, construction is expected to start this summer with completion in Q1 next year.

Jeanette Walker, Interim Director – Unity Campus, commented: “Domainex is one of Cambridge's longest established and most respected life science companies. We are looking forward to welcoming Tom and his team to Unity Campus.”

ENDS

Notes to editors

About Domainex Ltd.

Domainex is a leading, multi-award-winning, integrated medicines research service partner working with ambitious life science organisations from around the globe. The Company has been setting new standards in research since 2001, working collaboratively with pharmaceutical and biotechnology companies, patient foundations and leading academic institutions globally.

Domainex provides innovative and customised biology and chemistry services to advance the disease research projects of its partners, from target expression to pre-clinical development candidate nomination. Working with Domainex maximises the chance of successful progression for its partners’ research. Domainex’s innovative science and extensive technical capabilities produce novel candidate medicines to treat debilitating diseases. The team works closely and collaboratively with its partners to understand their aspirations, bringing ideas, know-how and a wealth of experience to bear on their projects.

Domainex’s highly qualified and experienced team of dedicated research scientists has an unrivalled breadth of knowledge, access to a wide range of technologies and a proven track record of successful innovation in solving research challenges, including being named on over 60 patent applications of numerous candidate drugs. The Company aims to deliver successful outcomes efficiently and quickly, setting the highest possible benchmark in medicines research.

Complete information about Domainex and its award-winning services can be found at www.domainex.co.uk

About Howard Group

Established in 1935 and with headquarters in the centre of Cambridge, Howard Group is a leading regional property investor and developer. The Group also provides growth capital funding strategic and management support to mid-sized businesses across a diverse range of sectors.

As a family-owned company, our name and our long-standing values run through everything we do. Now in our 86th year, we have built an enduring business by creating, nurturing and valuing lasting relationships. Our professionalism, transparency and commitment to delivery, coupled with a collaborative approach, means that we enjoy strong, long-lasting relationships with our partners.

Find out more: www.howard-ventures.com

For more information, contact:

Domainex
Dr. Tom Mander, CEO
E: tom.mander@domainex.co.uk

Sciad Communications
Juliette Craggs / Jasmin Shearan / Darya Shulakova
T: +44 (0)20 3405 7892
E: domainex@sciad.com

Howard Group
Jeanette Walker, Interim Director – Unity Campus
T: +44 (0)7540 100 512
E: j.walker@unitycampus.co.uk

Limewash
Sarah Brereton
T: +44 (0)7796 583 223
E: sarah@limewash.co.uk

Start your next project with Domainex

Contact one of our experts today